Drug Trial Radar · NCT06780332
Rapid Drug Desensitization Study in Adults Experiencing Hypersensitivity Reactions to Palynziq
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Feb 7, 2025
Primary completion
Aug 17, 2026
Study completion Aug 17, 2026
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Jan 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if rapid drug desensitization (RDD) to Palynziq will improve drug tolerability and treatment persistence in adult patients on commercial Palynziq experiencing hypersensitivity reactions (HSRs) leading to treatment interruption or reduction of dose or dosing frequency. See Section 10.8 for full list of HSR preferred terms. Study details include: * Study duration: Up to 30 weeks (up to 6 weeks for Screening, then RDD, and 24 weeks of follow-up) * RDD duration: 1 day * Palynziq dosing/follow-up duration: 24 weeks * Palynziq dosing frequency: Individualized
Conditions
- Phenylketonuria
- PKU
Interventions
RDD to PalynziqDrug
Delivery of gradually increasing doses of Palynziq at fixed time intervals over the course of several hours to a cumulative dose equal to the reactive dose. Reactive dose is defined as the dose at which the reactive HSR occurred which led to treatment interruption or reduction of dose or dose frequency.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine if RDD to Palynziq improves drug tolerability and treatment persistence in adults with PKU experiencing HSRs leading to treatment interruption or reduction of dose or dosing frequency (reactive HSR).Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Uncommon Cures
Chevy Chase, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.